Deutsche Bank Starts Prothena Corp (PRTA) at Buy

November 3, 2016 6:49 AM EDT
Get Alerts PRTA Hot Sheet
Price: $47.39 -6.18%

Rating Summary:
    11 Buy, 0 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 9
Trade PRTA Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Deutsche Bank initiated coverage on Prothena Corp (NASDAQ: PRTA) with a Buy rating and a price target of $73. Analyst Andrew Peters sees Prothena as a "compelling story."

"We view PRTA as a fundamentally strong story with a well-spaced catalyst path across three clinical stage programs. Indeed, lead program NEOD001 is currently enrolling two late-stage pivotal trials in AL Amyloidosis and we believe is poised to become the standard of care in an underserved and large market. Beyond the lead program however, we also point to promising early data, strong mechanistic rationale, and favorable economics for the Rochepartnered PRX002 in Parkinson's Disease. Despite our bullish view, our PT also reflects a conservative outlook on clinical risk and suggests meaningful upside on key catalysts," said Peters.

For an analyst ratings summary and ratings history on Prothena Corp click here. For more ratings news on Prothena Corp click here.

Shares of Prothena Corp closed at $45.13 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Deutsche Bank

Add Your Comment